Methods and compositions for enhanced delivery of macromolecules

Abstract

The invention provides compositions and methods that enhance the delivery of large macromolecules (i.e., greater than 10 kDa), such as antigen-binding polypeptides, across tight junctions. Such methods and compositions are particularly useful for delivering therapeutic antigen-binding polypeptides to the CNS, via intranasal administration, for the treatment of neurological disorders.

What is claimed is: 
     
         1 . A method for selective intranasal delivery of an antigen-binding polypeptide to the central nervous system of a patient, the method comprising administering to a patient in need thereof a composition comprising a penetration enhancer and an antigen-binding protein, wherein the penetration enhancer is Pz-peptide. 
     
     
         2 . The method of  claim 1 , wherein the antigen-binding polypeptide is an scFv. 
     
     
         3 . The method of  claim 1 , wherein the antigen-binding polypeptide specifically binds to a target antigen selected from the group consisting of TNF-alpha, amyloid beta, amyloid beta-derived diffusible ligand receptor, monoamine oxidase-B, L-3,4-dihydroxyphenylalanine decarboxylase, acetyl-coA carboxylase, N-methyl-D-aspartate aeceptor (also known as GRIN1), GRINA, GRIN2D, GRIN2C, GRIN3B, GRIN2A, GRIN2B, GRIN3A, histamine H1 Receptor, muscarinic receptor (also known as CHRM1), CHRM2, CHRM3, CHRM4, hypocretin receptor 1, hypocretin receptor 2, 5-hydroxytryptamine (also known as HTR1A), dopamine receptor (also known as DRD1), DRD2, DRD3, DRD4, DRD5, adrenergic beta 1 receptor, norepinephrin transporter (NET), and dopamine D2 receptor. 
     
     
         4 . The method of  claim 2 , wherein the scFv comprises an amino acid sequence with at least 80% similarity to SEQ ID No: 20, SEQ ID No: 21, SEQ ID No: 22, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 25, SEQ ID No: 26, or SEQ ID No: 27. 
     
     
         5 . The method of 2, wherein the scFv comprises a VH domain comprising an amino acid sequence with at least 80% similarity to SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, or SEQ ID No:35. 
     
     
         6 . The method of  claim 2 , wherein the scFv comprises a VL domain comprising an amino acid sequence with at least 80% similarity to SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, or SEQ ID No:34. 
     
     
         7 . The method of  claim 2 , wherein the scFv comprises an amino acid sequence with at least 80% similarity to SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, or SEQ ID No:33. 
     
     
         8 . The method of  claim 2 , wherein the scFv further comprises the amino acid sequence with at least 80% similarity to SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 36 or SEQ ID NO: 37. 
     
     
         9 . The method of  claim 1 , wherein the antigen-binding polypeptide is covalently linked to the penetration enhancer. 
     
     
         10 . The method of  claim 1 , wherein the patient has a neurological disorder. 
     
     
         11 . The method of  claim 10 , wherein the disorder is selected from the group consisting of migraine, depression, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, stroke, meningitis, amyotrophic lateral sclerosis, insomnia, meningitis, memory impairment, multiple sclerosis, narcolepsy, stroke, traumatic brain injury, and stress.